AbbVie's Mavyret Approved - FixHepC

This topic has 1 reply, 2 voices, and was last updated 7 years, 1 month ago by Iain.

Viewing 2 posts - 1 through 2 (of 2 total)

Author

Posts
4 August 2017 at 2:25 pm #26699
klhilde
- Topics: 30
- Replies: 223
- Total: 253
- Guardian Angel
@klhilde
Official price for eight weeks is set at US$26,400.

Mavyret is a combo of an NS3/4a inhibitor, Glecaprevir, and an NS5A inhibitor, Pibrentasvir.

Seattle Times: http://www.seattletimes.com/business/fda-oks-new-drug-to-treat-all-forms-of-hepatitis-c/
Fierce Pharma: http://www.fiercepharma.com/pharma/abbvie-s-new-pan-genotypic-hep-c-drug-mavyret-undercuts-competition
ABC: http://abcnews.go.com/Health/wireStory/fda-oks-drug-treat-forms-hepatitis-49019076
16 October 2017 at 4:13 am #26928
Iain
- Topics: 7
- Replies: 23
- Total: 30
- Treatment Warrior
@iain
Further on this, AbbVie have also announced approval for treatment of all genotypes in Japan has been granted.

https://news.abbvie.com/news/press-releases/abbvie-announces-approval-maviret-glecaprevirpibrentasvir-for-treatment-chronic-hepatitis-c-in-all-major-genotypes-gt1-6-in-japan.htm
Author

Posts

Viewing 2 posts - 1 through 2 (of 2 total)

You must be logged in to reply to this topic.